Survivors of Hodgkin lymphoma (HL) in childhood have an increased risk of subsequent malignant neoplasms (SMNs). Herein, the authors extended the follow-up of a previously reported Late Effects Study Group cohort and identified patients at highest risk for SMNs to create evidence for risk-based screening recommendations. METHODS: The standardized incidence ratio was calculated using rates from the Surveillance, Epidemiology, and End Results program as a reference. The risk of SMN was estimated using proportional subdistribution hazards regression. The cohort included 1136 patients who were diagnosed with HL before age 17 years between 1955 and 1986. The median length of follow-up was 26.6 years. RESULTS: In 162 patients, a total of 196 solid SMNs (sSMNs) were identified. Compared with the general population, the cohort was found to be at a 14-fold increased risk of developing an sSMN (95% confidence interval, 12.0-fold to 16.3-fold). The cumulative incidence of any sSMN was 26.4% at 40 years after a diagnosis of HL. Risk factors for breast cancer among females were an HL diagnosis between ages 10 years and 16 years and receipt of chest radiotherapy. Males treated with chest radiotherapy at age <10 years were found to be at highest risk of developing lung cancer. Survivors of HL who were treated with abdominal/pelvic radiotherapy and high-dose alkylating agents were found to be at highest risk of developing colorectal cancer and females exposed to neck radiotherapy at age <10 years were at highest risk of thyroid cancer. By age 50 years, the cumulative incidence of breast, lung, colorectal, and thyroid cancer was 45.3%, 4.2%, 9.5%, and 17.3%, respectively, among those at highest risk. CONCLUSIONS: Survivors of childhood HL remain at an increased risk of developing sSMNs. In the current study, subgroups of survivors of HL at highest risk of specific sSMNs were identified, and evidence for screening provided.
INTRODUCTION
Hodgkin lymphoma (HL) that is diagnosed and treated during childhood places survivors at an increased risk of developing subsequent malignant neoplasms (SMNs). [1] [2] [3] [4] [5] [6] Although previous studies have demonstrated that the risk of SMNs is significantly elevated and continues to increase with follow-up, to the best of our knowledge, the magnitude of risk with follow-up beyond 25 years remains unexplored. The current study extends the follow-up of the Late Effects Study Group (LESG) cohort, with the aim of identifying groups at highest risk and informing screening strategies for those at an increased risk of SMNs.
Cancer April 15, 2019 The LESG was established in 1979 as a multinational cohort of children diagnosed with HL and other cancers between 1955 and 1979 at age ≤16 years. 7 In 1994, the HL cohort was expanded to include 1380 patients from 15 institutions (first update) and the follow-up was extended to 11 years. 1 The second update occurred in 2001 and extended the median length of follow-up to 17 years. 8 The current report (which is the third update) extends the median length of follow-up beyond 25 years to address the gaps outlined above.
MATERIALS AND METHODS
A total of 11 LESG member institutions participated in the third update (see Supporting Information). Demographic and clinical data (including treatment of primary disease and recurrences up to 2001) were available from previous updates. 1, 8 For the third update, each participating site provided the clinical status of patients since 2001 , with details regarding any recurrence of HL (date of recurrence and associated therapeutic exposures), vital status (dead [date and cause of death] or alive [date of last contact]), and the development of a new SMN (date of diagnosis and site and histology of tumor). Pathology reports were reviewed by the respective institutional investigators to confirm the diagnosis of an SMN. Participating LESG member institutions obtained approval from respective Human Subjects Protection Agencies to abstract the required information from medical records.
Since the second update, only one hematologic malignancy (non-Hodgkin lymphoma) was reported. Therefore, the current update primarily focused on solid SMNs (sSMNs). Analyses were performed for all sSMNs, as well as for each subgroup of sSMN. The time at risk for sSMNs was computed from the date of diagnosis of HL to the date of diagnosis of sSMNs, the date of death, or the date of last contact, whichever came first. To estimate the risk of sSMNs, the number of person-years at risk under observation was compiled for the cohort. Annual age-specific and sex-specific incidence rates of cancer observed in the Surveillance, Epidemiology, and End Results (SEER) program 9 of the National Cancer Institute/National Institutes of Health were used as reference rates in the calculation of the expected number of cases. For earlier years for which the SEER rates were not available (before 1969), the rates of the earliest SEER year were used. The standardized incidence ratio (SIR) was calculated as the ratio of observed to expected numbers of cancer cases. For patients who developed multiple malignancies after a diagnosis of HL, all sSMNs were counted in the numerator of SIRs, in agreement with the SEER program's incidence calculation. 9 The absolute excess risk (AER) was calculated as an additional indicator of the impact of a diagnosis of HL and therapy on members of the cohort in comparison with the general population. The AER (expressed per 1000 person-years) was calculated by subtracting the expected number of sSMNs in the cohort from the observed number, dividing the difference by person-years of follow-up, and multiplying this number by 1000. Neoplasms not reported to the SEER database (basal cell carcinoma [BCC] and carcinoma in situ) were excluded from the calculation of SIRs and AERs. The cumulative incidence of sSMNs over time was calculated treating death as competing risk. 10 The cumulative incidence calculations were conducted both including and excluding BCC.
Patients were placed into 1 of 3 mutually exclusive groups based on therapeutic exposures as part of primary treatment or as salvage therapy for disease recurrence: radiotherapy (RT) alone, chemotherapy alone, and RT and chemotherapy.
Statistical Analysis
The relative risk of developing an sSMN was estimated using proportional subdistribution hazards regression, treating death as competing risk and using calendar time as the time scale. Explanatory variables were selected a priori and were evaluated for their simultaneous impact on developing an sSMN without any statistical selection. Variables included in the regression model were age at the time of diagnosis of HL (birth-9 years vs 10-16 years), sex, doxorubicin exposure (yes/no), alkylating agent score (AA score; ≥2 vs <2) (see Supporting Information), and site-specific RT (yes/no). The RT fields evaluated varied by sSMN type: any sSMN (any field); breast cancer (any field involving the chest [mediastinum, mantle, or lung]); lung cancer (any field involving the chest [mediastinum, mantle, or lung]); colorectal cancer (any field involving the abdomen or pelvis [inverted Y, para-aortic, liver, or spleen]); and thyroid cancer (any field involving the neck).
Statistical significance was defined as a 2-sided P value of <.05. SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) was used for all analyses.
RESULTS
The demographic and clinical characteristics of the cohort are detailed in Table 2) . By age 50 years, the cumulative incidence of any sSMN was 27.2% (95% CI, 23.2%-31.5%) (Fig. 1B) . Overall, the cohort was found to be at a 14-fold increased risk of developing an sSMN compared with the general population (SIR, 14.0; 95% CI, 12.0-16.3) ( Cancer April 15, 2019 diagnosis (Table 2 ) (Fig. 1C) . By age 50 years, the incidence of breast cancer was 23.5% (Table 2 ) (Fig. 1D ).
Of the 42 women with breast cancer, 9 developed contralateral breast cancer after a median of 5.9 years (range, 1.6-10.5 years). The incidence of a contralateral breast cancer was 26.6% at 10 years from diagnosis of the first breast cancer.
Patients with HL were found to be at a 25.8-fold increased risk of developing breast cancer when compared with the general population (95% CI, 19.3-fold to 33.5-fold) (P<.001) ( Table 3) . Those patients diagnosed with HL at age <10 years were at a 5.9-fold increased risk of developing breast sSMNs when compared with the general population, whereas those diagnosed with HL between ages 10 years and 16 years were found to be at a 32.7-fold increased risk (P = .004) ( Table 3 ). The AER for breast cancer was 23.3 per 1000 person-years for the cohort aged ≥40 years (see Supporting Table 2 ).
Multivariable regression (Table 4) identified the following risk factors: females diagnosed with HL between ages 10 years and 16 years (HR, 9.0; 95% CI, 2.8-55.4) and exposure to chest RT (HR, 5.0; 95% CI, 1.5-30.7).
Patients exposed to high-dose alkylating agents were found to be at a lower risk of developing breast cancer (HR, 0.5; 95% CI, 0.3-0.9).
Population at highest risk of developing breast cancer
Females treated with chest RT between the ages of 10 years and 16 years with no or low-dose alkylating agent exposure were at highest risk; the cumulative incidence of breast cancer was 45.3% by age 50 years (see Supporting Fig. 1A ).
Lung Cancer
Lung cancer was reported to have developed in 11 patients (10 of whom were male) after a median of 28 years (range, 12-34 years) from a diagnosis of HL. The median age at the time of diagnosis of lung cancer was 41 years (range, 22-46 years). The cumulative incidence of lung cancer was 2.2% by 40 years from a diagnosis of HL (Table 2) (Fig. 1E) and was 2.3% by age 50 years (Fig. 1F ). Males were found to be at a 26.7-fold increased risk when compared with the general population (95% CI, 13.4-fold to 16.7-fold), whereas females were at a 3.3-fold increased risk (95% CI, 0.2-fold to 14.6-fold) ( Table 3 ). The AER for Cancer April 15, 2019 lung cancer in male patients diagnosed with HL was 3.6 per 1000 person-years by age ≥40 years (see Supporting Table 2 ). All 11 cases of lung cancer developed in patients who had received chest RT.
Population at highest risk of developing lung cancer
Males treated with chest RT at age <10 years were found to be at highest risk; the cumulative incidence was 4.2% by age 50 years (see Supporting Fig. 1B ).
Colorectal Cancer
Colorectal cancer developed in 15 patients after a median of 25 years (range, 15-45 years) from a diagnosis of HL, yielding a cumulative incidence of 2.7% at 40 years (Table 2) (Fig. 1G) . By age 50 years, the cumulative incidence of colorectal cancer was 2.7% (Fig. 1H) . The cohort was at a 16.2-fold increased risk of developing colorectal cancer when compared with the general population (95% CI, 9.3-fold to 25.8-fold) ( Table 3 ). The AER for colorectal cancer was 2.8 per 1000 person-years by age ≥40 years (see Supporting Table 2 ). Multivariable analysis identified exposure to high-dose alkylating agents (HR, 5.1; 95% CI, 1.3-33.6) and abdominal/pelvic RT (HR, 3.6; 95% CI, 1.1-16.1) as 2 independent risk factors associated with developing colorectal cancer after a diagnosis of HL.
Population at highest risk of developing colorectal cancer
Survivors of HL who were treated with abdominal/pelvic RT and high-dose alkylating agents were found to be at the highest risk; the cumulative incidence of colorectal cancer was 9.5% by age 50 years (see Supporting Fig. 1C ).
Thyroid Cancer
Thyroid cancer developed in 30 patients after a median of 27 years (range, 7-45 years) from a diagnosis of HL and at a median age of 34.5 years (range, 13-53 years) Cancer April 15, 2019 ( Table 1 ). The cumulative incidence of thyroid cancer was 5.5% at 40 years from the time of the HL diagnosis (Fig. 1I) ; by age 50 years, the cumulative incidence was 4.4% (Fig. 1J) . Patients with HL were found to be at a 27.7-fold increased risk of developing thyroid cancer compared with the general population (95% CI, 18.9-fold to 38.8-fold). The AER for thyroid cancer was 3.5 per 1000 person-years for patients with HL by age ≥40 years (see Supporting Table 2 ). Multivariable analysis demonstrated that the risk of thyroid cancer was higher in females (HR, 2.1; 95% CI, 1.0-4.4) and in those treated at age <10 years (HR, 3.0; 95% CI, 1.4-6.7). Approximately 93% of thyroid cancers developed in the RT field, thereby precluding evaluation of RT as a risk factor.
Population at highest risk of developing thyroid cancer
Females exposed to neck RT at age <10 years were found to be at highest risk; the cumulative incidence of thyroid cancer approached 17.3% by age 50 years (see Supporting  Fig. 1D ).
Sensitivity Analysis
At the time of data abstraction, a total of 595 patients had not experienced an event (SMN or death); contact was documented with 36% of patients within the 5 years prior to December 31, 2012. To alleviate potential problems related to incomplete follow-up, sensitivity analyses were performed in which all patients who had not experienced an event (death or development of an SMN) were censored as of December 31, 2012, irrespective of their actual date of last contact. It was assumed that those lost to follow-up did not develop an SMN. With these extremely conservative assumptions, a lower boundary was placed on the reported estimates. The results of the sensitivity analyses are presented in Supporting Table 3 .
DISCUSSION
In the current update of the LESG cohort followed for a median of >26 years, the cumulative incidence of developing an sSMN was 26.4% at 40 years after a diagnosis of HL. By age 50 years, the cumulative incidence of an sSMN was 27.2%. The cohort was found to be at a 14-fold increased risk of developing an sSMN compared with the general population, with an AER of 6.7 per 1000 person-years. In the previous update of the LESG cohort in 2001 in which the median length of followup was 17 years, the SIR was higher (18.5) whereas the AER was similar (6.5). 8 A large cohort of 5-year survivors of HL from the United States (Childhood Cancer Survivor Study; CCSS) with a median follow-up of 23 years found the SIR of an sSMN to be 8.7, the AER to be 6.9, and the 30-year cumulative incidence to be 18.4%. 3 In a recent report regarding patients with HL from the CCSS who were followed into the fifth and sixth decades, the SIR for a new-onset sSMN (ie, without any previous sSMN) was 3.6 and the AER was 3.3 per 1000 person-years. 11 The SIR of any subsequent primary neoplasm among 5-year survivors of HL in the British Childhood Cancer Survivor Study (BCCSS) was 5.6 and the AER was 31.3. 12 The present LESG cohort was followed from the time of a diagnosis of HL, thereby precluding the likelihood of missing information regarding patients who could have developed an sSMN and died within the first 5 years. Furthermore, the LESG cohort included therapeutic exposures from the time of a diagnosis of HL until the development of the index SMN (including exposures for the management of HL recurrence); to our knowledge this differs from the other cohorts that were limited to therapeutic exposure surrounding the initial diagnosis or to the first 5 years after diagnosis. A sufficiently large number of patients in follow-up allowed us to provide relatively stable estimates of the risk of sSMNs up to 40 years from the time of diagnosis of HL and up to the age of 50 years. In keeping with previous reports, no upper age limit for the discontinuation of screening was identified for any type of sSMN in the LESG cohort. 3, [11] [12] [13] In contrast to previously published studies, the current study investigated the risk of sSMN in patients with HL separately and in addition described the highest risk populations.
A major goal of the current study was to develop evidence with which to guide the screening of survivors of HL for the development of sSMNs. Specifically, we wanted to provide the magnitude of excess risk compared with that of the general population to determine benefit from screening; latency between the diagnosis of HL and the diagnosis of sSMN to determine when to initiate screening compared with the diagnosis of HL and exposure to genotoxic agents; incidence of sSMNs as a function of age to determine at what age to initiate screening and whether there is an upper age limit for screening discontinuation; and, finally, to create a profile of survivors of HL who are at highest risk of specific sSMNs to identify subpopulations that would benefit the most from screening.
The results of the current study provide evidence of the markedly elevated risk of breast cancer in female survivors of HL, which was reported as a 25.8-fold increased risk when compared with the general population, with Cancer April 15, 2019 a cumulative incidence exceeding 20% at 40 years from the time of the diagnosis of HL and exceeding 25% by age 50 years. The median latency between the diagnoses of HL and breast cancer was 25 years; the shortest interval was 10 years. The incidence of breast cancer starts to increase at age 25 years and remains elevated at least until age 50 years. Taken together, these findings provide additional evidence for initiating surveillance at either 8 years after the diagnosis of HL or at age 25 years, whichever occurs later. We identified those patients at highest risk of developing breast cancer (ie, those diagnosed with HL between ages 10-16 years, those treated with chest RT, and those who had received no or very low-dose alkylating agents); by age 50 years, the risk of breast cancer in this high-risk group was 45.3%, which is comparable to the risk in BRCA1 mutation carriers (24% to 67% by age 50 years). 14 We believe that this group of survivors of HL would benefit the most from initiating screening at age 25 years or 8 years from the time of diagnosis of HL (whichever occurs later). These recommendations are in keeping with those presented by the Children's Oncology Group 15 and the International Late Effects of Childhood Cancer Guideline Harmonization Group 16 with regard to female childhood, adolescent, and young adult cancer survivors who are treated with chest RT. Findings from the current study also add evidence for the impact of age at the time of exposure on the risk of developing sSMNs. Furthermore, we determined that the risk of contralateral breast cancer was 26% at 10 years after diagnosis of the first breast cancer, which is very similar to the risk of contralateral breast cancer noted among women carrying BRCA1 mutations at 10 years after the first breast cancer, 17 again providing evidence for considering surgical or chemoprophylaxis to prevent contralateral breast cancer.
Survivors of HL were found to be at a 16.3-fold increased risk of developing lung cancer when compared with the general population; this risk was significantly higher in male survivors of HL at 26.7-fold. The shortest interval between the diagnosis of HL and that of lung cancer was 12 years. All cases of lung cancer developed within the RT field. To the best of our knowledge, the BCCSS is the only earlier study to examine the risk of lung cancer after a diagnosis of childhood HL, although it lacked information regarding RT exposure and reported an AER of 1.7 per 1000 person-years among 5-year survivors aged >40 years. 12 This finding is in keeping with the corresponding AER of 2.4 noted in this age group in the LESG cohort. The lack of information regarding tobacco use in the current study, as well as the BCCSS study, needs to be acknowledged, as well as the necessity of future studies of lung cancer risk with and without smoking. The subgroup of individuals found to be at highest risk in the LESG cohort were male patients with HL who were treated with chest RT at age <10 years, in whom the cumulative incidence of lung cancer was 4.2% by age 50 years, thus representing a subgroup of patients who would benefit from screening beginning at approximately 10 years to 12 years from the time of diagnosis of HL. This risk exceeded that observed among male smokers (2% by age 50 years). 18 Results from the National Lung Screening Trial demonstrated the potential of low-dose computed tomography to detect lung cancer at earlier stages, thereby decreasing mortality. 19 To the best of our knowledge, the question of whether the use of low-dose computed tomography will benefit survivors of HL at highest risk of developing lung cancer is unknown. A large, definitive randomized trial is logistically impossible to perform to answer this question, but modeling and microsimulation may be used to address it.
We determined that survivors of HL were at a 16.2-fold increased risk of developing colorectal cancer when compared with the general population; the shortest interval between the diagnosis of HL and colorectal cancer was found to be 12 years. The subgroup of survivors of HL at highest risk of developing colorectal cancer included those treated with abdominal/pelvic RT and high-dose alkylating agents, in whom the cumulative incidence approached 9.5% by age 50 years, and the observed increase in risk began at age 25 years. This risk is higher than that observed in individuals with ≥2 first-degree relatives affected with colorectal cancer (1.2% by age 50 years), 20 in whom the recommendations included the initiation of screening colonoscopy at approximately age 40 years or 10 years younger than the youngest family member with colorectal cancer, and to have shorter intervals between procedures. 21 The current study cohort was found to be at a 27.7-fold increased risk of thyroid cancer, with the shortest interval being 7 years between the diagnosis of HL and that of thyroid cancer. Females exposed to neck RT at age <10 years were at the highest risk; the cumulative incidence approached 17.3% by age 50 years. Based on these findings, surveillance is recommended. The modality of screening could be the result of shared decision making between the patient and health care provider, as recommended by the International Late Effects of Childhood Cancer Guideline Harmonization Group. 22 The current study needs to be placed within the context of its limitations. First, we were unable to capture nontherapeutic exposures (eg, tobacco, alcohol, or diet). Second, the cohort included patients diagnosed at least 30 years previously, thus making the cohort vulnerable to attrition. The median length of follow-up for patients who developed an sSMN (32.3 years; range, 4-57 years) was longer than that of those patients who did not (17.6 years; range, 0-54 years) (P<.0001); the lack of complete follow-up could have resulted in either overestimation or underestimation of the true magnitude of risk. To account for this, we artificially extended follow-up of the unaffected cohort to 2012, thus creating a lower bound to the estimates observed such that the true risk would reside somewhere between that reported and the lower bound. Third, we did not collect information concerning the patients' surveillance history (modality or frequency); enhanced screening due to increased awareness possibly could have resulted in an increased incidence. Fourth, we did not include RT dose in our risk estimation; this was a purposeful decision because we wanted the observations to serve as a practical guide for clinicians who are providing care to survivors of HL knowing that these clinicians often do not have ready access to information regarding the RT dose. We acknowledge that the more contemporarily treated patients with HL may have less exposure to RT, both with respect to dose and volume. 23 However, for the cohort of patients treated between 1955 and 1986, it is clear that continued surveillance for sSMNs is essential because their risk continues to increase as these survivors enter their fourth and subsequent decades of life. The CCSS recently reported that patients with HL treated in the 1990s are at an increased risk of developing an sSMN, although the magnitude is lower than that observed for those individuals treated in the 1970s. 23 These findings support the need for continued surveillance of patients with HL, regardless of the era in which they were treated. Finally, the magnitude of risk for lung and colorectal sSMNs needs to be viewed with caution because the absolute numbers observed were relatively small. These limitations notwithstanding, in this large cohort of patients diagnosed with childhood HL and followed for >25 years, we identified subgroups of patients with HL at highest risk of developing specific sSMNs. The results of the current study also provide evidence for screening parameters in these high-risk subgroups, both with respect to HL diagnosis as well as the attained age of the survivor of HL.
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